Cargando…
Challenges of Clinical Trial Design for Targeted Agents Against Pediatric Leukemias
The past 40 years have seen significant improvements in both event-free and overall survival for children with acute lymphoblastic and acute myeloid leukemia (ALL and AML, respectively). Serial national and international clinical trials have optimized the use of conventional chemotherapeutic drugs a...
Autores principales: | Mussai, Francis Jay, Yap, Christina, Mitchell, Christopher, Kearns, Pamela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285052/ https://www.ncbi.nlm.nih.gov/pubmed/25610810 http://dx.doi.org/10.3389/fonc.2014.00374 |
Ejemplares similares
-
Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies
por: Fultang, Livingstone, et al.
Publicado: (2021) -
Targeted Nanoparticles for Pediatric Leukemia Therapy
por: Basha, Riyaz, et al.
Publicado: (2014) -
Targeted Drug Discovery for Pediatric Leukemia
por: Napper, Andrew D., et al.
Publicado: (2013) -
The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated‐recombinant arginase I BCT‐100
por: De Santo, Carmela, et al.
Publicado: (2017) -
Radiation in Combination With Targeted Agents and Immunotherapies for Pediatric Central Nervous System Tumors - Progress, Opportunities, and Challenges
por: Qiu, Bo, et al.
Publicado: (2021)